Empagliflozin (CAS 864070-44-0)

Application and positioning

Empagliflozin is an SGLT2 inhibitor supplied as the free base. It is used in oral tablets for type 2 diabetes and for heart failure, with cardiovascular outcome data in both settings. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Linagliptin (CAS 668270-12-0)
• Sotagliflozin (CAS 1018899-04-1)
• Trelagliptin Succinate (CAS 1029877-94-8)
• Alogliptin benzoate (CAS 850649-62-6)
• Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-alpha-D-glucopyranoside (CAS 1279691-36-9)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.